HRTIS.HE
Strong SellSinkerHerantis Pharma Oyj · Healthcare · Finland · $51M · Avg Vol: $43K/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT HERANTIS PHARMA OYJ
Read
Herantis Pharma Oyj is a clinical-stage biotechnology company focused on developing disease-modifying therapies for Parkinson's disease. The company's lead candidate, HER-096, is a blood-brain barrier-penetrating peptidomimetic designed to protect and restore dopaminergic neurons. Its competitive position is anchored by strong intellectual property and a novel therapeutic approach targeting the underlying pathophysiology of neurodegeneration.
FINANCIAL SUMMARY (EUR)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS (EUR) | -2.31 | -0.64 | 0.02 | -0.24 | -0.27 | — | -0.27 | -0.16 | -0.18 | — |
| Shares | — | 16.9M | 20.2M | 20.2M | 24.1M | +42.5% | 26.5M | — | — | — |
| Debt | — | 4.5M | 34.8K | 30.0K | 24.9K | -82.4% | 20.1K | — | — | — |
| Equity | — | -60.3K | 4.7M | -0.2M | -1.7M | — | — | — | — | — |
| Op CF | — | -8.9M | -4.6M | -6.5M | -6.1M | — | -6.1M | — | — | — |
| Inv CF | — | -0.2M | 0.6M | -0.5M | -0.2M | — | — | — | — | — |
| Fin CF | — | 8.6M | 4.5M | 2.2M | 6.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HRTIS.HE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HRTIS.HE | Herantis Pharma Oyj(you) | $51M | 5 | Strong Sell |
| FARON.HE | Faron Pharmaceuticals Oy | $97M | 5 | Strong Sell |
| NANOFH.HE | Nanoform Finland Oyj | $86M | 31 | Sell |
| AIFORIA.HE | Aiforia Technologies Oyj | $74M | 3 | Strong Sell |
| HEALTH.HE | Nightingale Health Oyj | $65M | 13 | Strong Sell |
| OPTOMED.HE | Optomed Oyj | $59M | 16 | Strong Sell |
| MODU.HE | Modulight Oyj | $51M | 32 | Sell |
| NXTMH.HE | Nexstim Plc | $79M | 27 | Sell |
| REG1V.HE | Revenio Group Oyj | $435M | 44 | Hold |
| ORIOLA.HE | Oriola Oyj | $191M | 67 | Buy |
Peer medians: ROE -9.5% · P/E 19.5x · Gross margin 65.9%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.